A-Synuclein

Alpha-synuclein preformed fibrils: a tool to understand Parkinson’s disease and develop disease modifying therapy

A-Synuclein, Biomarkers, Parkinson's Disease, Pre-PD /

Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized by multiple motor and non-motor symptoms, which include, among others, constipation, sleep disturbance, bradykinesia, gait and balance abnormalities, muscle stiffness and resting tremor. The motor symptoms are caused by progressive age-related death of dopaminergic neurons and in the vast majority of patients suffering from […]

Alpha-synuclein preformed fibrils: a tool to understand Parkinson’s disease and develop disease modifying therapy Read More »

Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates

A-Synuclein, Gut-Brain axis /

. This study does not support the hypothesis of a transmission of a-synuclein pathology through the vagus nerve and the dorsal motor nucleus of the vagus. Instead, our results suggest a possible systemic mechanism in which the general circulation would act as a route for long-distance bidirectional transmission of endogenous a-synuclein between the enteric and

Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates Read More »

Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson’s Disease

A-Synuclein, Fecal Transplants (FMT), Iron, Pre-PD /

We argue that there is significant evidence that bacterial inflammagens fuel this systemic inflammation, and might be central to thedevelopment of PD. We also discuss the processes whereby bacterial inflammagens may be involved in causing nucleation of proteins, including of α-Syn. Lastly, we review evidence that iron chelation, pre-and probiotics, as well as antibiotics and

Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson’s Disease Read More »

Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson’s disease

A-Synuclein, Biomarkers, Pre-PD /

In human post-mortem liver tissue, we identifed cases with neuropathologically confrmed α-syn pathology containing α-syn within hepatocellular structures to a higher degree (75%) than control subjects without α-syn accumulation in the brain (57%). Our results reveal that α-syn accumulates within the liver and may be derived from the brain or other peripheral sources. Collectively, our

Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson’s disease Read More »

The cell biology of Parkinson’s disease

A-Synuclein, Parkinson's Disease /

Parkinson’s disease (PD) is a progressive neurodegenerative disorder resulting from the death of dopamine neurons in the substantia nigra pars compacta. Our understanding of PD biology has been enriched by the identification of genes involved in its rare, inheritable forms, termed PARK genes. These genes encode proteins including α-syn, LRRK2, VPS35, parkin, PINK1, and DJ1, which can

The cell biology of Parkinson’s disease Read More »

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease

A-Synuclein, Biomarkers, Pre-PD /

This review article aims to summarize useful biomarkers for the diagnosis of PD, as well as the biomarkers used to monitor disease progression. This review article describes the role of α-Syn in PD and how it could potentially be used as a biomarker for PD. Also, preclinical and clinical investigations encompassing genetics, immunology, fluid and

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease Read More »

Presynaptic accumulation of α-synuclein causes synaptopathy and progressive neurodegeneration in Drosophila

A-Synuclein, Biomarkers, Pre-PD /

Taken together, our results presented here indicate α-syn accumulation in presynaptic terminals affects synaptic proteins and active zone integrity that impair neuronal function. The resultant synaptopathy causes behavioural deficits and progressive age-related neurodegeneration. Thissuccession of phenotypes recapitulates key events of dying-back like neurodegeneration5,27,92 and provide insights into the pathogenic mechanisms underlying synaptopathy, the likely initiating

Presynaptic accumulation of α-synuclein causes synaptopathy and progressive neurodegeneration in Drosophila Read More »

An Overview of Alpha Synuclein Protein and Its Role in Parkinson’s disease

A-Synuclein, Dementia - Lewy Bodies, Uncategorized /

Under pathologic conditions, cellular accumulation of misfolded α-synuclein oligomers and aggregates are observed in a group of neurodegenerative diseases called synucleinopathies. The mechanisms of how α-synuclein protein takes part in the neurodegeneration process and physiologic roles of the protein have not been fully elucidated yet. It’s important to unravel the secrets of this protein and

An Overview of Alpha Synuclein Protein and Its Role in Parkinson’s disease Read More »

Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson’s disease

A-Synuclein, Biomarkers /

Our results reveal that α-syn accumulates within the liver and may be derived from the brain or other peripheral sources. Collectively, our findings indicate that the liver may play a role in the clearance and detoxification of pathological proteins in PD and related synucleinopathies. CLICK TO REVIEW

Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson’s disease Read More »

Novel targeted therapies for Parkinson’s disease

A-Synuclein, Biomarkers, Iron, Pre-PD /

Large biomarker development programs are undertaken to identify disease signatures that will improve patient selection and outcome measures in clinical trials. In this review, we summarize PD-related mechanisms that can serve as targets of therapeutic interventions aiming to slow or modify disease progression, as well as previous and ongoing clinical trials in each field, and

Novel targeted therapies for Parkinson’s disease Read More »